What are the precautions for dordaviprone-Modeyso?

In the clinical study of dordaviprone-Modeyso in the treatment of diffuse midline glioma, warnings and precautions such as hypersensitivity,QTC interval prolongation, and embryo-fetal toxicity appeared. Discontinue and resume at reduced dose upon recovery, or permanently discontinue based on severity.

1. Allergy: Modeyso may cause severe allergic reactions. Signs and symptoms of hypersensitivity reactions may include rash, hives, fever, low blood pressure, wheezing, or swelling of the face or throat. Inform patients of the signs and symptoms of allergic reactions and instruct them to seek immediate medical attention if symptoms occur. If a clinically significant hypersensitivity or anaphylactic reaction occurs, discontinue use of MODEYSO immediately and initiate appropriate medical therapy and supportive care.

2. QTc interval prolongation: Modeyso can cause concentration-dependent QTc interval prolongation, thereby increasing the risk of ventricular tachyarrhythmias (such as torsade de pointes) or sudden death. Monitor ECG and electrolytes before initiating treatment and then periodically during treatment as clinically indicated. When MODEYSO is taken with other drugs known to have the potential to prolong the QT interval, the QT interval may be significantly prolonged. Avoid concurrent use of MODEYSO with products known to prolong the QT interval. If combined use cannot be avoided, use MODEYSO and QT extension products separately.

Increase the frequency of monitoring when using MODEYSO in patients taking other drugs known to have the potential to prolong the QT interval, in patients with congenital long QT syndrome, existing QTc prolongation, a history of ventricular arrhythmias, electrolyte abnormalities, heart failure, or in patients taking strong or moderate CYP3A4 inhibitors. The dose of MODEYSO should be interrupted or reduced in patients who develop QT prolongation, and Modeyso should be permanently discontinued in patients who develop signs of life-threatening arrhythmias.

3. Embryo-Fetal toxicity: Based on findings from animal studies and its mechanism of action, Mycoplasma can cause fetal damage when administered to pregnant women. In embryo-fetal development studies, oral administration of dordaviprone to pregnant rats and rabbits during organogenesis resulted in embryo-fetal lethality, growth alterations, and structural abnormalities at exposures below the highest recommended human dose.

Inform pregnant women and women of reproductive potential of the potential risks to the fetus. Advise females of reproductive potential to use effective contraception during treatment with MODEYSO and for 1 month after the last dose. Advise male patients with a female partner of reproductive potential to use an effective method of contraception during treatment with MODEYSO and for 1 month after the last dose.

In summary,Although Modeyso has shown certain efficacy in the treatment of diffuse midline glioma, its potential side effects, especially allergic reactions, QTc interval prolongation and embryo-fetal toxicity, require great attention. Medical workers should always pay attention to patient safety when performing treatment and formulate individualized treatment plans to minimize the occurrence of adverse reactions. By strengthening monitoring and rational medication guidance, patients can be provided with a safer and more effective treatment experience.

Reference materials:https://www.drugs.com/modeyso.html